Currently, monoclonal antibodies targeting 4-1BB, such as urelumab and utomilumab, have been used in the treatment of B-cell non-Hodgkin lymphoma, lung cancer, breast cancer, soft tissue sarcoma, and other solid tumors (56). Here, TNFRSF9 is linked to soft tissue sarcoma.